Myriad Genetics Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Myriad Genetics (MYGN) Misses Q3 EPS by 13c, Updates Guidance
November 1, 2022 9:06 AM EDTMyriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.19), $0.13 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $156.4 million versus the consensus estimate of $170.58 million.
GUIDANCE:
Myriad Genetics sees FY2022 EPS of ($0.35)-($0.30), versus the consensus of... More
